mitotic spindle organizing protein 1 pseudogene 2Genealiases: []
Q-omics provides the consensus-scored MZT1P2 profile across patient tissues and cancer cell-line models. MZT1P2 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MZT1P2 is differentially expressed in 10, with the highest sampling consensus in KIRP. Additionally, MZT1P2 RNA expression shows 13,316 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ACC, KIRP, and THYM as cancer lineages where MZT1P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MZT1P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MZT1P2 survival associations across molecular data types. MZT1P2 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MZT1P2 RNA expression–survival associations across cancer types. High MZT1P2 expression shows unfavorable associations in ACC, KIRC and COAD, but favorable associations in LAML, BLCA and STAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MZT1P2 RNA expression.
This table summarizes MZT1P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for MZT1P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MZT1P2 shows lower tumor expression in KICH and BRCA and higher tumor expression in KIRP, BLCA, HNSC and LIHC. The KIRP box plot shows higher MZT1P2 RNA expression in tumor versus normal tissue (log2 FC = +0.308, t-test p = .009).
This table shows molecular features associated with MZT1P2 in patient tissues and cancer cell lines. In patient samples, MZT1P2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
